AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27348852 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat®
Number of subjects: 60
Study 27348852 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro™ White Varnish
Number of subjects: 60
Study 27348852 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Varnish™
Number of subjects: 60
Study 27348852 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace™ Varnish
Number of subjects: 60
Study 27348852 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Pro® Varnish
Number of subjects: 60
Study 27348852 — intervention group
Group type: COMPARATOR
Intervention: Control (no varnish)
Number of subjects: 60
Study 25837634 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐eCPD module (n = 80)
Number of subjects: 168
Study 25837634 — intervention group
Group type: EXPERIMENTAL
Intervention: Live genetic CPD module (n = 88)
Number of subjects: 168
Study 25837634 — intervention group
Group type: EXPERIMENTAL
Intervention: Live training
Number of subjects: 168
Study 25837634 — intervention group
Group type: COMPARATOR
Intervention: Online oncogenetics training
Number of subjects: 168
Study 25837634 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive website
Number of subjects: 168
Study 24229688 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO plus CsA
Number of subjects: 36
Study 24229688 — intervention group
Group type: COMPARATOR
Intervention: rhTPO alone
Number of subjects: 36
Study 19476985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, slow-release transdermal glyceryl trinitrate (GTN) patch
Number of subjects: 29
Study 19476985 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (no immediate treatment for PSA recurrence)
Number of subjects: 29
Study 19476985 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (GTN)
Number of subjects: 29
Study 18177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip participants with hyposensitive altered sensations
Number of subjects: 93
Study 18177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip participants with altered midface sensation
Number of subjects: 93
Study 18177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cleft lip participants
Number of subjects: 93
Study 18177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip participants
Number of subjects: 93
Study 18177194 — intervention group
Group type: COMPARATOR
Intervention: Noncleft participants
Number of subjects: 93
Study 14993623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP) - 25 mg/kg of sulfadoxine and 1.25 mg/kg of pyrimethamine
Number of subjects: 80
Study 14993623 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) - 25 mg/kg
Number of subjects: 80
Study 14993623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP)
Number of subjects: 80
Study 15570192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (10 mg) methamphetamine hydrochloride
Number of subjects: 8
Study 15570192 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (20 mg) methamphetamine hydrochloride
Number of subjects: 8
Study 15570192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (10 mg and 20 mg)
Number of subjects: 8
Study 10597969 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum hygienic protocol
Number of subjects: 200
Study 10597969 — intervention group
Group type: COMPARATOR
Intervention: Limited aseptic precautions
Number of subjects: 200
Study 7572649 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal symptom-limited exercise ergometric stress testing (Ex)
Number of subjects: 397
Study 7572649 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dipyridamole (0.7 to 0.8 mg/kg) stress testing (Dip)
Number of subjects: 397
Study 7572649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.7 to 0.8 mg/kg) plus nonlimited exercise stress testing (Dip+Ex)
Number of subjects: 397
Study 7572649 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (0.7 to 0.8 mg/kg) stress testing (Dip)
Number of subjects: 397
Study 2149285 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 240 mg daily
Number of subjects: 650
Study 2149285 — intervention group
Group type: COMPARATOR
Intervention: Toremifene 60 mg daily
Number of subjects: 650
Study 2149285 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20-40 mg daily
Number of subjects: 650
Study 7015988 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol (80 mg b.i.d.)
Number of subjects: 18
Study 7015988 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (50 mg b.i.d.)
Number of subjects: 18
Study 7015988 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol + prazosin (3-5 mg b.i.d.)
Number of subjects: 18
Study 7015988 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol + prazosin (3-5 mg b.i.d.)
Number of subjects: 18
Study 7015988 — intervention group
Group type: COMPARATOR
Intervention: prazosin (3-5 mg b.i.d.) alone
Number of subjects: 18
Study 29605229 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Soothing Condition
Number of subjects: 60
Study 29605229 — intervention group
Group type: COMPARATOR
Intervention: Failed Soothing Condition
Number of subjects: 60
Study 28535546 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar interlaminar epidural injections
Number of subjects: 360
Study 26084343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri SD5865
Number of subjects: 21
Study 26084343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25153092 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone CBT
Number of subjects: 0
Study 25153092 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face CBT
Number of subjects: 0
Study 25153092 — intervention group
Group type: COMPARATOR
Intervention: Phone CBT
Number of subjects: 0
Study 25153092 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22937725 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with ropivacaine 0.75%
Number of subjects: 108
Study 22937725 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with ropivacaine 0.75%
Number of subjects: 108
Study 22937725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 108
Study 19953810 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Dyract AP)
Number of subjects: 45
Study 19953810 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (Fuji IILC)
Number of subjects: 45
Study 19953810 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity glass ionomer cement (Fuji IX)
Number of subjects: 45
Study 19953810 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 45
Study 17296625 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Physical Component Summary (PCS)
Number of subjects: 1058
Study 17296625 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Mental Component Summary (MCS)
Number of subjects: 1058
Study 17296625 — intervention group
Group type: COMPARATOR
Intervention: ICD therapy for ventricular tachyarrhythmias
Number of subjects: 1058
Study 17296625 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shocks
Number of subjects: 1058
Study 15073389 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 38
Study 15073389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15073389 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA
Number of subjects: 38
Study 15073389 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering light
Number of subjects: 38
Study 12634563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade isthmic spondylolisthesis group
Number of subjects: 40
Study 12634563 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade isthmic spondylolisthesis group
Number of subjects: 40
Study 12634563 — intervention group
Group type: COMPARATOR
Intervention: Pediatric control group
Number of subjects: 40
Study 12634563 — intervention group
Group type: COMPARATOR
Intervention: Adult control group
Number of subjects: 40
Study 12634563 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of low-grade and high-grade isthmic spondylolisthesis
Number of subjects: 40
Study 12634563 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Meyerding-Newman scores
Number of subjects: 40
Study 12634563 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of spondylolisthesis groups with controls
Number of subjects: 40
Study 9649979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 50
Study 9649979 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 50
Study 7654893 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA treatment (100 mL, twice daily enemas of sodium acetate 80 mmol/L, sodium propionate 30 mmol/L and sodium butyrate 40 mmol/L)
Number of subjects: 40
Study 7654893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7654893 — intervention group
Group type: EXPERIMENTAL
Intervention: SCFA treatment
Number of subjects: 40
Study 30878970 — intervention group
Group type: EXPERIMENTAL
Intervention: VIG (70% VO2peak)
Number of subjects: 188
Study 30878970 — intervention group
Group type: EXPERIMENTAL
Intervention: BIKE
Number of subjects: 188
Study 30878970 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups (BIKE, MOD, VIG)
Number of subjects: 188
Study 30878970 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 188
Study 29223437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2149
Study 29223437 — intervention group
Group type: COMPARATOR
Intervention: Heparin with or without GPI
Number of subjects: 2149
Study 26173169 — intervention group
Group type: EXPERIMENTAL
Intervention: Algisyl‐LVR
Number of subjects: 11
Study 23759284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient rate control
Number of subjects: 614
Study 23759284 — intervention group
Group type: COMPARATOR
Intervention: Strict rate control
Number of subjects: 614
Study 20660556 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion/obesity prevention program (Challenge!) delivered by college‐aged black mentors
Number of subjects: 235
Study 20660556 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study 20660556 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion/obesity prevention program (Challenge!)
Number of subjects: 235
Study 17175075 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion (jaw clenching)
Number of subjects: 30
Study 17175075 — intervention group
Group type: COMPARATOR
Intervention: No occlusion
Number of subjects: 30
Study 15870629 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 ingestion (0.2 g x kg(‐1))
Number of subjects: 7
Study 15870629 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo, 0.138 g x kg(‐1))
Number of subjects: 7
Study 12049015 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Ropivacain (R) infusion
Number of subjects: 20
Study 12049015 — intervention group
Group type: COMPARATOR
Intervention: Epidural Bupivacain (B) infusion
Number of subjects: 20
Study 10613613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (80 mg)
Number of subjects: 36
Study 10613613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroguanide (200 mg)
Number of subjects: 36
Study 10613613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and Chloroguanide (combined)
Number of subjects: 36
Study 7778068 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg subcutaneous
Number of subjects: 12
Study 7778068 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg subcutaneous
Number of subjects: 12
Study 7778068 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg intravenous
Number of subjects: 12
Study 2140250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 micrograms/kg
Number of subjects: 90
Study 2140250 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study 6999545 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen tablets
Number of subjects: 32
Study 6999545 — intervention group
Group type: COMPARATOR
Intervention: Naproxen suppositories
Number of subjects: 32
Study 31373162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration protocols (GA, GB, GC, GD, GE)
Number of subjects: 195
Study 31373162 — intervention group
Group type: COMPARATOR
Intervention: Dehydration (GF)
Number of subjects: 195
Study 31565913 — intervention group
Group type: EXPERIMENTAL
Intervention: HICT modified‐ FIFA 11+ exercise
Number of subjects: 39
Study 31565913 — intervention group
Group type: COMPARATOR
Intervention: Standard FIFA 11+
Number of subjects: 39
Study 27940648 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire thrombectomy
Number of subjects: 206
Study 27940648 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 206
Study 26495289 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme LMA
Number of subjects: 505
Study 26495289 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 505
Study 26495289 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal LMA
Number of subjects: 505
Study 26495289 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube Suction-D
Number of subjects: 505
Study 26495289 — intervention group
Group type: COMPARATOR
Intervention: SLIPA
Number of subjects: 505
Study 23433601 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211 + sitagliptin
Number of subjects: 18
Study 23433601 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211
Number of subjects: 18
Study 23433601 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 18
Study 21375606 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-grass pollen sublingual immunotherapy tablets
Number of subjects: 0
Study 21375606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19685003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecabet sodium (ES)
Number of subjects: 14
Study 19685003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17709354 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A received routine postoperative advice and a three-day prescription of paracetamol, ibuprofen, and codeine.
Number of subjects: 88
Study 17709354 — intervention group
Group type: COMPARATOR
Intervention: Group B used the Wong-Baker Faces Pain Scale.
Number of subjects: 88
Study 15042276 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 59
Study 15042276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11979408 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 0
Study 11979408 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval appendectomy
Number of subjects: 0
Study 11979408 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated appendicitis treatment
Number of subjects: 0
Study 9657576 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg)
Number of subjects: 16
Study 9657576 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 16
Study 9657576 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 microg)
Number of subjects: 16
Study 9657576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8109489 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid pretreatment (32-mg oral dose of methylprednisolone administered 6-24 hr before and again 2 hr before injection)
Number of subjects: 1155
Study 8109489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered in the same time periods)
Number of subjects: 1155
Study 2764287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural anesthesia without hemodilution (Group 1)
Number of subjects: 30
Study 2764287 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution without epidural anesthesia (Group 2)
Number of subjects: 30
Study 2764287 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution during lumbar epidural anesthesia (Group 3)
Number of subjects: 30
Study 1095631 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride (300 mg)
Number of subjects: 10
Study 1095631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1095631 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 10
Study 31556542 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal biofeedback training involving cycling augmented by functional electrical stimulation (FES) and balance exercises (15 sessions of FES-cycling training followed by 15 sessions of balance training, 20 minutes each) in addition to usual care (70 minutes)
Number of subjects: 68
Study 31556542 — intervention group
Group type: COMPARATOR
Intervention: Usual care (30 sessions, 90 minutes)
Number of subjects: 68
Study 31556542 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal biofeedback training
Number of subjects: 68
Study 31234848 — intervention group
Group type: EXPERIMENTAL
Intervention: UK Patient Activation Measure (PAM-13)
Number of subjects: 57
Study 31234848 — intervention group
Group type: EXPERIMENTAL
Intervention: Think aloud interviews with PAM-13
Number of subjects: 57
Study 29016336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (MBZ) 500 mg chewable tablet
Number of subjects: 295
Study 25659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT)
Number of subjects: 968
Study 25659194 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 968
Study 24377409 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy (average of 97 sessions, range: 25-205)
Number of subjects: 35
Study 24377409 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (minimal treatment)
Number of subjects: 35
Study 22249412 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Measured Blood Pressure (SMBP)
Number of subjects: 57
Study 19568355 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg triamcinolone acetonide
Number of subjects: 44
Study 19568355 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg triamcinolone acetonide
Number of subjects: 44
Study 19568355 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg triamcinolone acetonide
Number of subjects: 44
Study 19568355 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 44
Study 17475891 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gp120 vaccination
Number of subjects: 530
Study 17475891 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 530
Study 15755868 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT-EVP (sequential estradiol valerate plus progestin)
Number of subjects: 88
Study 15755868 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT-EV (estradiol valerate alone)
Number of subjects: 88
Study 15755868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 88
Study 12062464 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (levo‐alpha‐acetylmethadol)
Number of subjects: 62
Study 12062464 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 62
Study 10656038 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral penicillin
Number of subjects: 150
Study 10656038 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg DEC/kg
Number of subjects: 150
Study 10656038 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral penicillin plus 1 mg DEC/kg
Number of subjects: 150
Study 10656038 — intervention group
Group type: EXPERIMENTAL
Intervention: local antibiotics
Number of subjects: 150
Study 10656038 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study 8521712 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous levonorgestrel treatment with subdermal implants (Norplant)
Number of subjects: 22
Study 8521712 — intervention group
Group type: COMPARATOR
Intervention: Depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 22
Study 2245269 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment during the Sheffield Psychotherapy Project
Number of subjects: 40
Study 2245269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive therapy
Number of subjects: 40
Study 2245269 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory therapies
Number of subjects: 40
Study 493227 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic anaesthesia
Number of subjects: 0
Study 493227 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with halothane
Number of subjects: 0
Study 29696832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (100 mg)
Number of subjects: 7
Study 29696832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 27356530 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg soft gelatin capsule (marketed formulation)
Number of subjects: 73
Study 27356530 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg hard gelatin capsule
Number of subjects: 73
Study 27356530 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg soft gelatin capsules with 300 mg MDC8
Number of subjects: 73
Study 27356530 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg soft gelatin capsules with 100 mg MDC8
Number of subjects: 73
Study 24796660 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of Suicide (SOS) program
Number of subjects: 0
Study 24796660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22710616 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 91
Study 22710616 — intervention group
Group type: COMPARATOR
Intervention: Healthcare professional-led asthma program
Number of subjects: 91
Study 20092962 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radiotherapy (CRT)
Number of subjects: 218
Study 20092962 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 218